Rx00196 - Pramipexole


Name:
Pramipexole
Rx ID:
Rx00196
Validation Level:
Phenomic Similarity:
0.591
Reference ID:
DB00413
Primary Indications:
Pediatric Tourette syndrome
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Idiopathic Parkinson's disease; Restless Legs Syndrome
Pathways:
Monoamine GPCRs; Amine ligand-binding receptors; GPCRs, Class A Rhodopsin-like; Nicotine Activity on Dopaminergic Neurons; Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics; Hypothetical Networ ...Click to show more
Drug Interactions:
Cimetidine; Dihydrocodeine; Paliperidone; Thiothixene; Triprolidine; Ziprasidone Zuclopenthixol;
Food Interactions:
Take without regard to meals, however if nausea is a problem, taking the product with food may reduce its incidence.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00196
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Chemical, Pharmacological and Biological Annotations


ATC Code:
N04BC05
Brands:
Glepark (Glenmark); Medopexol (Medochemie); Miramel (Clonmel); Miraper (Specifar); Mirapexin (Boehringer Ingelheim); Pexola (Boehringer Ingelheim); Sifrol (Boehringer Ingelheim); Sifrol ER (Boehringer Ingelheim)
Categories:
Antioxidants; Antiparkinson Agents; Dopamine Agonists; Antidyskinetics
ChEBI ID:
8356
KEGG Drug ID:
D00559
SMILE:
CCCN[C@H]1CCC2=C(C1)SC(N)=N2
InChI:
1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Heterocyclic Compounds
Class:
Azoles
Subclass:
Thiazoles
Indication:
For the treatment of signs and symptoms of idiopathic Parkinson's disease
Pharmacodynamics:
Pramipexole is a nonergot dopamine agonist with high relative <i>in vitro</i> specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The rele...
Click to show more...
Description:
Pramipexole is a medication indicated for treating Parkinson's disease and restless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache or to counteract the problems with low libido experienced by so...
Click to show more...
Mechanism:
The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Inhibitor
CYP450 2C19 substrate:
Inhibitor
CYP450 inhibitory promiscuity:
High CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.8676 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org